A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Arcus Biosciences, Inc.
Merck Sharp & Dohme LLC
Toray Industries, Inc
AstraZeneca
Northwestern University
Valerio Therapeutics